---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022133"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:35:20.880341+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase

## Summary
- Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.
- Net loss $6.6M vs $5.7M in Q3 2024; Adjusted EBITDA -$6.0M vs -$4.6M.
- Closed purchase of all U.S. assets for Ameluz and RhodoLED from Biofrontera AG; earnout reduced to 12-15% of net sales.
- Divested Xepi antibiotic cream to Pelthos Pharmaceuticals for $3M closing plus up to $6M milestones.
- Cash $3.4M at Sep 30; additional $2.5M received in Oct; runway extended by asset purchase and divestiture.

## SEC filing metadata
- accession: 0001493152-25-022133
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/0001493152-25-022133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022133
- JSON: https://secwatch.observer/filing/0001493152-25-022133.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.